

14 September 2023

India | Equity Research | Company Update

Archean Chemical Industries

Speciality Chemicals

Bromine is a good chemical play amid China overcapacity

Bromine prices have dropped below 15-year low in China in Jun'23, but it has partly recovered in Aug'23. The price fall was a mix of greed, speculation and sudden drop in demand. China is undergoing destocking which may last till end-CY23 as per ICL. We fundamentally like bromine producers as China is significantly dependent on imports to meet its demand, and thus, it cannot create overcapacity. Archean Chemical's (ACI) Q1FY24 result was relatively better despite the volatility in bromine prices due to long-term contracts, and strong performance in industrial salts. We expect bromine to witness volume recovery by Q4FY24E, and prices to firm up only in FY25E. ACI is also in the process of commissioning its derivative plant which increases earnings visibility during the forecasted period.

We maintain **BUY** on ACI with an unchanged target price of INR 750 (13x FY25 EPS). Key risks: 1) Lower than expected bromine prices and volume recovery; and 2) delay in bromine derivative plant commissioning.

Bromine is a relatively better play

Global chemical industry has been adversely impacted in the past few months due to global end-industry destocking, lower demand from China and chemicals overcapacity in China. Amid these uncertainties, we prefer chemicals that are relatively better placed vs China overcapacity. One such commodity is bromine, where China is dependent on imports, and Chinese domestic production is significantly lower compared to its demand.

China bromine spot price was highly impacted due to a peculiar situation of 'greed' and speculation. The average bromine price between **Jan 1, '17 and Dec 31, '20** was USD 4.46/kg at China spot market with peak prices at USD 5.32/kg and lowest price at USD 3.59/kg. However, average bromine price jumped to USD 7.55/kg with peak prices at USD 10.87/kg and lowest price at USD 5.17/kg between **Jan 1, '21 and Dec 31, '22**. The price jump was due to supply-chain disruption and strong demand.

Financial Summary

Y/E March (INR mn)	FY22A	FY23A	FY24E	FY25E
Net Revenue	11,304	14,411	14,914	21,268
EBITDA	4,672	6,340	6,456	10,106
EBITDA Margin (%)	41.3	44.0	43.3	47.5
Net Profit	1,882	3,826	4,564	7,137
EPS (Rs)	19.5	31.1	37.1	58.0
EPS % Chg YoY	182.6	59.1	19.3	56.4
P/E (x)	31.7	19.9	16.7	10.7
EV/EBITDA (x)	14.4	11.7	11.3	6.8
RoCE (%)	28.9	33.1	25.5	30.9
RoE (%)	112.3	45.2	27.8	32.7

Sanjesh Jain

sanjesh.jain@icicisecurities.com
+91 22 6807 7153

Akash Kumar

akash.kumar@icicisecurities.com

Ashvik Jain

ashvik.jain@icicisecurities.com

Market Data

Market Cap (INR)	76bn
Market Cap (USD)	919mn
Bloomberg Code	ACI IN
Reuters Code	ARCN.BO
52-week Range (INR)	732 /440
Free Float (%)	44.0
ADTV-3M (mn) (USD)	2.3

Price Performance (%)	3m	6m	12m
Absolute	10.3	(2.6)	0.0
Relative to Sensex	7.3	17.7	13.4

ESG Disclosure	2021	2022	Change
ESG score	-	-	-
Environment	-	-	-
Social	-	-	-
Governance	-	-	-

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: Bloomberg, I-sec research

Previous Reports

15-08-2023: [Q1FY24 results review](#)

30-05-2023: [Q4FY23 results review](#)

TBBA (flame retardant) players have imported huge quantities of bromine and its derivatives as long-term contracts and spot price from ICL, and Albemarle was at USD 4-5/kg during the period of high China spot price. Traders saw arbitrage benefit, which led to large imported volumes of bromine / TBBA by end-CY22. When demand crashed and supply-chain normalised, China was left with huge imported volumes of TBBA. This dragged China spot bromine price to fall sharply in CY23-TD with average bromine price at USD 3.92/kg, peak price at USD 6.37/kg and lowest price at USD 2.49/kg. The current China spot bromine price stands at USD 3.37/kg.

If we assume the period between **Jan 1, '17 and Dec 31, '20** to be normal and representative, the current China bromine spot price is still below the lowest price during the representative period. This implies bromine price has not fully recovered despite a price jump of 35% from lows of Jun'23. We attribute reasons for low China bromine price as: **1)** Inventory situation has improved, but excess inventory has still not been completely liquidated; and **2)** construction is among large-end applications, and China is facing challenging times in real estate market which has affected demand.

Exhibit 1: China spot bromine price averaged USD 4.46/kg during CY17-20




Source: I-Sec research, Bloomberg

Exhibit 2: China spot bromine price averaged USD 7.55/kg during CY21-22



Source: I-Sec research, Bloomberg

Exhibit 3: China spot bromine price dipped below 15-year low in Jun'23, but has recovered in the past two months



Source: I-Sec research, Bloomberg

Why Indian bromine price collapsed?


India bromine spot price has also collapsed despite India market not carrying excess TBBA inventory. India has large local bromine producers – ACI, Agrocell-Solaris and Satyesh Brine Chem that are dependent on exports. Bromine is a continuous manufacturing process, and it requires specialised tanks (nickel or lead lined) for storage. ACI has ~300 ISO tanks suitable for storing bromine, and others have even lower number of tanks. The global practice of bromine storage is in the form of TBBA which is solid, and can be stored in sack bags.

Indian bromine producers are not forward integrated to manufacture TBBA, and doesn't have large bromine storage facilities. Therefore, they were forced to sell bromine at a distress price to TBBA / other derivative producers. ACI is in the process of adding TBBA capacity by Q1FY25.

Bromine volumes may recover in FY24E, prices may improve at best in FY25E for ACI

ACI is likely to benefit from bromine volume recovery by Q4FY24E. ACI has large annual contracts coming for renewal in Q2FY24, and considering current bromine price is muted, contract renewal price will be at lower price vs FY23. Bromine realisation for ACI in Q1FY24 was USD 3.9/kg (vs current China bromine spot price at USD 3.4/kg), this implies ACI bromine realisation may continue to dip in near-term despite some recovery in China bromine spot price in post two months. However, we anticipated bromine sales volumes to grow for ACI. We are estimating ACI bromine sales volume at 20.kte (up 10% YoY) for FY24E and 25.7kte (+25%) for FY25E.


Domestic price contracts are for 3-4 months, and therefore, price recovery in domestic market may continue helping ACI bromine realisation as bromine prices march towards normalisation over the next few quarters. We have assumed ACI bromine realisation at USD 3.78/kg for FY24E, and USD 3.8/kg for FY25E.

Exhibit 4: Bromine volumes for ACI may recover from Q4FY24E


Source: I-Sec research, Company data

Industrial salt realisation was a silver lining for ACI

In the past couple of quarters, ACI had faced headwinds for its bromine business; however, ACI's Q1FY24 EBITDA had small dip due to higher realisation in industrial salts. Industrial salt fresh contracts were at a higher price driving the blended realisation to USD 24/te in FY23 vs USD 19/te in FY22. ACI has one large customer for industrial salt where it has renewed contracts at a higher price for two years. This provides visibility for higher ACI industrial salt realisation for the forecasted period. ACI is also in the process of adding two more washeries which may expand its industrial salt capacity from 3.6mn tpa to 5mn tpa.

Exhibit 5: Industrial salt performance is a silver lining for ACI


Source: I-Sec research, Company data

Re-rating catalysts from ramp up in sales of bromine derivative and lease renewal

We see two valuation re-rating triggers for ACI – **1)** successful commissioning of bromine derivative plant. ACI is in the process of commissioning derivative plant entirely by Q1FY25 with clear brine fluid and PTA (capacity of 18ktpa) catalyst plant to start by end-FY24, and TBBA (10ktpa) production to commence in Q1FY25; and **2)** land lease renewal. ACI's land is under the renewal process for 30years till CY47.

The rise in contribution from bromine derivative may help ACI branch out into more value-added products, and forward integration will help in capturing more bromine value. Further, the company's earnings may benefit from higher bromine consumption, which is its highest margin business. ACI has started an R&D centre in Jhagadia (in

Gujarat) which may help initially in sampling its bromine derivatives, support sales to ramp-up bromine derivatives plant. It will also aid in new product development over the next few years.

Key comments on bromine business by ICL Group during earnings for QE Jun'23


- 'The recovery (bromine business) and demand for flame retardants which was expected in the second half of the year has not materialised. For the second quarter, lower demand resulted in increased competition and lower prices.'
- "...elemental bromine prices hit lows, not seen since 2008 and 2009 and low price flame retardant supply remained in the market. Once again, results vary significantly by end market. Weakness in electronics continued and was magnified by a slow return to growth in China than had been projected, while building and construction end markets remained soft as well. Meanwhile, demand for clear brine fluids and our specialty minerals was stable in Q2.'
- 'We're suffering from the cycle like everybody else. It's a significant downturn because, normally, when there's a slowdown, we produce a little less. We take the disciplined approach. We demonstrate the value to our customers, and are usually able to affect the strong pricing.'
- 'Currently, the drop in demand is significant. There was so much stock built up in the supply chain. It has just taken quite a while to get that stuck out of the supply chain, and the demand has still not built back up. I'm talking about the demand for TVs, laptops, cell phones, still the demand is not back. Construction, which is also a significant component, there the cycle is longer.'
- 'So, electronics is expected to come back quickly, for refill of product, on construction, given the interest rates, and overall activity globally, it's going to take longer, put that together with abundant supply. That as I said, due to the dynamics that have caused the pricing to go down below the cost of some of our competitors, supply is going to come down somewhat in the coming months. And as supply normalises a little bit, and as demand normalises, we expect to go back to normal.'
- 'So, we're going to lose less of volume in the next few months, and we're going to allow the market to take its course for a few more months, until we get back to normal. We believe in the fundamental strength of the market. We're going through the bottom side of a cycle, bottom that hasn't happened for 15 years. We were sure that the market is coming back. And, the only question is how many more months we'll have to endure the current situation.'
- 'We're positive that we're not going to see a significant return to normalised business in Q3. The jury is still out, but typically the fourth quarter is a weaker quarter. Customers are not looking to build up stock towards the end of the year. So, we'll start seeing some significant improvement in the beginning of 2024.'

Exhibit 6: Shareholding pattern

%	Dec'22	Mar'23	Jun'23
Promoters	53.6	53.6	53.6
Institutional investors	35.8	35.7	34.8
MFs and others	15.4	15.0	14.5
FIs/Banks	12.1	12.8	13.0
Insurance	2.3	2.5	3.2
FIIIs	6.0	5.5	4.1
Others	10.6	10.7	11.6

Source: Bloomberg

Exhibit 7: Price chart



Source: Bloomberg

Financial Summary

Exhibit 8: Profit & Loss

(INR mn, year ending March)

	FY22A	FY23A	FY24E	FY25E
Net Sales	11,304	14,411	14,914	21,268
Operating Expenses	6,633	8,071	8,458	11,162
EBITDA	4,672	6,340	6,456	10,106
EBITDA Margin (%)	41.3	44.0	43.3	47.5
Depreciation & Amortization	669	686	766	999
EBIT	4,003	5,654	5,690	9,107
Interest expenditure	1,617	970	39	39
Other Non-operating Income	-	-	-	-
Recurring PBT	2,510	5,117	6,105	9,545
Profit / (Loss) from Associates	-	-	-	-
Less: Taxes	628	1,291	1,541	2,409
PAT	1,882	3,826	4,564	7,137
Less: Minority Interest	-	-	-	-
Extraordinaries (Net)	-	-	-	-
Net Income (Reported)	1,882	3,826	4,564	7,137
Net Income (Adjusted)	1,882	3,826	4,564	7,137

Source Company data, I-Sec research

Exhibit 9: Balance sheet

(INR mn, year ending March)

	FY22A	FY23A	FY24E	FY25E
Total Current Assets	3,986	5,770	7,065	13,276
of which cash & cash eqv.	587	327	1,348	5,749
Total Current Liabilities & Provisions	1,735	1,517	1,157	1,016
Net Current Assets	2,251	4,253	5,908	12,260
Investments	112	2,101	2,101	2,101
Net Fixed Assets	11,033	11,461	13,598	13,400
ROU Assets	406	450	450	450
Capital Work-in-Progress	172	362	362	362
Total Intangible Assets	-	-	-	-
Other assets	291	318	336	444
Deferred Tax assests	-	3	3	3
Total Assets	15,313	17,554	21,004	27,124
Liabilities				
Borrowings	8,449	215	215	215
Deferred Tax Liability	92	1,155	1,155	1,155
Provisions	3	0	1	1
Other Liabilities	1,952	-	(447)	(638)
Equity Share Capital	193	246	246	246
Reserves & Surplus	2,434	14,064	18,321	24,773
Total Net Worth	2,627	14,310	18,567	25,019
Minority Interest	-	-	-	-
Total Liabilities	15,313	17,554	21,004	27,124

Source Company data, I-Sec research

Exhibit 10: Quarterly trend

(INR mn, year ending March)

	Sep-22	Dec-22	Mar-23	Jun-23
Net Sales	2,935	3,649	3,824	3,431
% growth (YOY)		18.7	2.6	(14.3)
EBITDA	1,186	1,599	1,944	1,347
Margin %	40.4	43.8	50.8	39.3
Other Income	189	75	83	109
Extraordinaries	-	-	-	-
Adjusted Net Profit	636	981	1,365	940

Source Company data, I-Sec research

Exhibit 11: Cashflow statement

(INR mn, year ending March)

	FY22A	FY23A	FY24E	FY25E
Operating Cashflow	4,793	6,531	4,916	7,697
Working Capital Changes	(1,648)	(1,570)	(1,099)	(2,249)
Capital Commitments	(966)	(999)	(2,904)	(800)
Free Cashflow	2,179	3,962	913	4,648
Other investing cashflow	(135)	(1,905)	454	477
Cashflow from Investing Activities	(135)	(1,905)	454	477
Issue of Share Capital	-	7,886	-	-
Interest Cost	(1,977)	(1,626)	(39)	(39)
Inc (Dec) in Borrowings	(135)	(8,234)	-	-
Dividend paid	-	-	(308)	(685)
Others	(124)	(146)	-	-
Cash flow from Financing Activities	(2,237)	(2,120)	(347)	(724)
Chg. in Cash & Bank balance	(193)	(62)	1,021	4,401
Closing cash & balance	122	60	1,348	5,749

Source Company data, I-Sec research

Exhibit 12: Key ratios

(Year ending March)

	FY22A	FY23A	FY24E	FY25E
Per Share Data (INR)				
Reported EPS	19.5	31.1	37.1	58.0
Adjusted EPS (Diluted)	19.5	31.1	37.1	58.0
Cash EPS	26.5	36.7	43.3	66.1
Dividend per share (DPS)	-	2.5	5.6	20.3
Book Value per share (BV)	27.3	116.3	150.9	203.3
Dividend Payout (%)	-	8.0	15.0	35.0
Growth (%)				
Net Sales	52.6	27.5	3.5	42.6
EBITDA	78.1	35.7	1.8	56.5
EPS (INR)	182.6	59.1	19.3	56.4
Valuation Ratios (x)				
P/E	31.7	19.9	16.7	10.7
P/CEPS	23.4	16.9	14.3	9.4
P/BV	22.7	5.3	4.1	3.0
EV / EBITDA	14.4	11.7	11.3	6.8
EV/SALES	6.0	5.1	4.9	3.2
Dividend Yield (%)	-	0.4	0.9	3.3
Operating Ratios				
Gross Profit Margins (%)	96.5	99.8	97.8	93.8
EBITDA Margins (%)	41.3	44.0	43.3	47.5
Effective Tax Rate (%)	25.0	25.2	25.2	25.2
Net Profit Margins (%)	16.6	26.5	30.6	33.6
NWC / Total Assets (%)	10.1	10.4	11.7	16.3
Net Debt / Equity (x)	3.0	(0.2)	(0.2)	(0.3)
Net Debt / EBITDA (x)	1.7	(0.3)	(0.5)	(0.8)
Profitability Ratios				
RoCE (%)	28.9	33.1	25.5	30.9
RoE (%)	112.3	45.2	27.8	32.7
RoIC (%)	16.1	26.7	30.8	26.0
Fixed Asset Turnover (x)	1.0	1.3	1.1	1.6
Inventory Turnover Days	39.0	42.5	44.5	46.5
Receivables Days	49.4	29.8	31.8	33.8
Payables Days	36.3	24.2	14.2	4.2

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Sanjesh Jain, PGDM; Akash Kumar, MBA; Ashvik Jain, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Prabodh Ayadhoot](mailto:Mr.Prabodh.Ayadhoot) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
